Dr Reddy's Soars with 14.5% Profit Surge

Dr Reddy's Laboratories posted a remarkable 14.5% increase in consolidated profit after tax, reaching Rs 1,437 crore for the quarter ending September 30. The Hyderabad-based pharmaceutical giant attributes this growth to robust sales in its branded markets.

The company reported a profit after tax of Rs 1,255 crore during the same quarter last year. This financial ascent is complemented by a rise in revenue, which increased to Rs 8,805 crore from Rs 8,016 crore in the previous year, according to a regulatory filing by Dr Reddy's Laboratories.

Co-Chairman and Managing Director GV Prasad highlighted the impact of branded market momentum and consistent contributions from the Nicotine Replacement Therapy portfolio, which balanced the decline in US Lenalidomide sales. Dr Reddy's continues to concentrate on strengthening its core business while advancing key pipeline assets and exploring new business development initiatives.